TG Therapeutics, Inc. (BIT:1TGTX)
Italy
· Delayed Price · Currency is EUR 40.00
+0.78 (1.99%)
At close: May 2, 2025
TG Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | 329 | 233.66 | 2.79 | 6.69 | 0.15 | Upgrade
|
| Revenue Growth (YoY) | 40.80% | 8290.02% | -58.36% | 4300.66% | - | Upgrade
|
| Cost of Revenue | 38.49 | 14.13 | 0.27 | 0.79 | - | Upgrade
|
| Gross Profit | 290.52 | 219.53 | 2.52 | 5.9 | 0.15 | Upgrade
|
| Selling, General & Admin | 154.3 | 122.71 | 95.48 | 128.09 | 107.85 | Upgrade
|
| Research & Development | 94.29 | 76.19 | 125.35 | 222.58 | 165.9 | Upgrade
|
| Operating Expenses | 248.59 | 198.9 | 220.84 | 350.67 | 273.75 | Upgrade
|
| Operating Income | 41.93 | 20.63 | -218.32 | -344.77 | -273.59 | Upgrade
|
| Interest Expense | -24.03 | -12.62 | -10.19 | -5.64 | -6.33 | Upgrade
|
| Other Non Operating Income (Expenses) | 7.69 | 5.04 | 4.7 | 2.31 | 0.54 | Upgrade
|
| Pretax Income | 25.59 | 13.06 | -223.81 | -348.1 | -279.38 | Upgrade
|
| Income Tax Expense | 2.21 | 0.39 | - | - | - | Upgrade
|
| Net Income | 23.38 | 12.67 | -223.81 | -348.1 | -279.38 | Upgrade
|
| Net Income to Common | 23.38 | 12.67 | -223.81 | -348.1 | -279.38 | Upgrade
|
| Net Income Growth | 84.52% | - | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 145 | 142 | 135 | 132 | 115 | Upgrade
|
| Shares Outstanding (Diluted) | 160 | 149 | 135 | 132 | 115 | Upgrade
|
| Shares Change (YoY) | 7.96% | 9.67% | 2.41% | 14.64% | 30.51% | Upgrade
|
| EPS (Basic) | 0.16 | 0.09 | -1.65 | -2.63 | -2.42 | Upgrade
|
| EPS (Diluted) | 0.15 | 0.09 | -1.65 | -2.63 | -2.42 | Upgrade
|
| EPS Growth | 68.03% | - | - | - | - | Upgrade
|
| Free Cash Flow | -40.56 | -31.41 | -176.18 | -296.04 | -214.86 | Upgrade
|
| Free Cash Flow Per Share | -0.25 | -0.21 | -1.30 | -2.24 | -1.86 | Upgrade
|
| Gross Margin | 88.30% | 93.95% | 90.48% | 88.19% | 100.00% | Upgrade
|
| Operating Margin | 12.74% | 8.83% | -7838.99% | -5154.28% | -179996.05% | Upgrade
|
| Profit Margin | 7.11% | 5.42% | -8036.34% | -5204.08% | -183803.29% | Upgrade
|
| Free Cash Flow Margin | -12.33% | -13.44% | -6326.18% | -4425.70% | -141357.90% | Upgrade
|
| EBITDA | 42 | 20.84 | -218.01 | -344.49 | -273.44 | Upgrade
|
| EBITDA Margin | 12.77% | 8.92% | - | - | - | Upgrade
|
| D&A For EBITDA | 0.07 | 0.21 | 0.3 | 0.28 | 0.16 | Upgrade
|
| EBIT | 41.93 | 20.63 | -218.32 | -344.77 | -273.59 | Upgrade
|
| EBIT Margin | 12.74% | 8.83% | - | - | - | Upgrade
|
| Effective Tax Rate | 8.64% | 2.99% | - | - | - | Upgrade
|
| Revenue as Reported | 329 | 233.66 | 2.79 | 6.69 | 0.15 | Upgrade
|
Source: S&P Global Market Intelligence. Standard template. Financial Sources.